Update on Extended Treatment for Venous Thromboembolism [PDF]
, 2018 The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge +7 more
core +2 more sources
Frontiers in Pharmacology, 2022 The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects.
Robert Hoerr +3 more
doaj +1 more source
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies [PDF]
, 2013 Background: Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic VTE; their use could avoid ...
Alexander T Cohen +12 more
core +2 more sources
Challenges in Trials in Sickle Cell Disease: Thromboprophylaxis in Sickle Cell Disease With Central Venous Catheters (THIS) Pilot Study. [PDF]
J Clin ApherABSTRACT Individuals with sickle cell disease (SCD) often require central venous catheter (CVC) use; however, this is associated with a high incidence of venous thromboembolism (VTE). We conducted a pilot randomized controlled trial (RCT) to assess if it is feasible and safe to conduct an adequately powered RCT comparing rivaroxaban to placebo as ...
Abdulrehman J +6 more
europepmc +2 more sources
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. [PDF]
, 2020 Introduction This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of ...
Camm, AJ +9 more
core +1 more source
Rivaroxaban versus warfarin for the management of left ventricle thrombus
The Egyptian Heart Journal, 2021 Background Rivaroxaban has been recently introduced for the management of non-valvular intra-cardiac thrombosis with variable results. We aimed to compare the results of the off-label use of rivaroxaban versus warfarin in the management of patients with ...
Monirah A. Albabtain +7 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or ...
Tingting Zhao +17 more
doaj +1 more source
Blood loss in primary total knee arthroplasty-body temperature is not a significant risk factor-a prospective, consecutive, observational cohort study [PDF]
, 2015 BACKGROUND: Hypothermia related to anaesthesia and operating theatre environment is associated with increased blood loss in a number of surgical disciplines, including total hip arthroplasty.
Beller, Elaine +5 more
core +2 more sources
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
Gastroenterology Research and Practice, 2016 Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods.
Muhammed Sherid +7 more
doaj +1 more source
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source